Skip to main navigation Skip to search Skip to main content

Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin e Synthase-1 adversely affects the postoperative survival in non-small cell lung cancer

  • Yu Chung Wu
  • , Li Jen Su
  • , Hao Wei Wang
  • , Chien Fu Jeff Lin
  • , Wen Hu Hsu
  • , Teh Ying Chou
  • , Chi Ying F. Huang
  • , Chia Li Lu
  • , Chung Tsen Hsueh

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: Cyclooxygenase (COX)-2 and microsomal prostaglandin E synthase (mPGES)-1 have been found to be overexpressed in non-small cell lung cancer (NSCLC). The aim of this study was to investigate the expression profiles of COX-2 and mPGES-1 and their correlation with the clinical characteristics and survival outcomes in patients with resected NSCLC. Methods/Results: Seventy-nine paired adjacent normal-tumor matched samples were prospectively procured from patients undergoing surgery for NSCLC. The protein levels of COX-2 and mPGES-1 were assessed by Western blot analysis. Overexpression in the tumor sample was defined as more than twofold increase in protein expression compared with the corresponding adjacent normal tissue. Co-overexpression of COX-2 and mPGES-1 were further confirmed by immunohistochemistry. COX-2 was overexpressed in 58% and mPGES-1 in 70% of the tumor samples (p < 0.0001). Co-overexpression of mPGES-1 and COX-2 was noted in 43%, and they were unrelated to each other (p = 0.232). Co-overexpression of both proteins was significantly associated with less tumor differentiation (p = 0.046), tumor size larger than 5 cm (p = 0.038), and worse survival status during the follow-up (p = 0.036). Multivariate analysis showed that in addition to overall stage, co-overexpression of both proteins adversely affected the overall (hazard ratio, 2.40; p = 0.045) and disease-free survivals (hazard ratio, 2.27; p = 0.029). Conclusions: Overexpression of either COX-2 or mPGES-1 is common but unrelated in NSCLC. Co-overexpression of both COX-2 and mPGES-1 adversely affects postoperative overall and disease-free survivals. © 2010 by the International Association for the Study of Lung Cancer.
Original languageEnglish
Pages (from-to)1167-1174
Number of pages8
JournalJournal of Thoracic Oncology
Volume5
Issue number8
DOIs
StatePublished - Aug 2010

ASJC Scopus Subject Areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Keywords

  • Cyclooxygenase-2
  • Microsomal prostaglandin E synthase-1
  • Non-small cell lung cancer
  • Survival
  • Prognosis
  • Prospective Studies
  • Cyclooxygenase 2/metabolism
  • Humans
  • Middle Aged
  • Male
  • Survival Rate
  • Carcinoma, Non-Small-Cell Lung/metabolism
  • Blotting, Western
  • Immunoenzyme Techniques
  • Intramolecular Oxidoreductases/metabolism
  • Lung Neoplasms/metabolism
  • Prostaglandin-E Synthases
  • Aged, 80 and over
  • Adenocarcinoma/metabolism
  • Adult
  • Female
  • Aged
  • Neoplasms, Squamous Cell/metabolism
  • Carcinoma, Large Cell/metabolism

Cite this